Hi,
moomoo ID:NaN
Log Out
English
Back
Log in to access Online Inquiry
Multi-dimentional Analyses
Company Valuation Capital Tracking Short Selling Data
01858 CHUNLI MEDICAL
15.500
+0.280+1.84%
YOY
Do not show
Hide blank lines
(Q9)2022/09/30(Q6)2022/06/30(Q3)2022/03/31(FY)2021/12/31
Turnover
5.79% 759.96M 18.39% 571.39M 13.45% 257.11M 18.18% 1.11B
Operating income
5.79% 759.96M 18.39% 571.39M 13.45% 257.11M 18.18% 1.11B
Operating expenses
-18.58% -198.48M -28.42% -145.59M 11.35% -50.21M 1.30% -253.6M
Gross profit
1.90% 561.49M 15.31% 425.8M 21.72% 206.9M 25.53% 854.54M
Selling expenses
1.55% -230.17M -8.68% -155.01M -24.04% -79.9M -41.92% -342.05M
Administrative expenses
-15.36% -24.68M -13.54% -15.46M -8.06% -6.01M 1.76% -30.67M
Research and development expenses
-61.11% -105.01M -111.19% -72.29M -124.70% -33.11M -44.41% -104.84M
Revaluation surplus
-- 6.54M -- 3.96M -- 1.7M -- --
-Changes in the fair value of other assets
-- 6.54M -- 3.96M -- 1.7M -- --
Impairment and provision
-4.13% -13.43M -63.90% -16.78M 16.95% -5.03M -338.47% -27.29M
-Other impairment is provision
-4.13% -13.43M -63.90% -16.78M 16.95% -5.03M -338.47% -27.29M
Operating interest expense
94.68% 16.58M 8.00% 5.78M -63.31% 1.41M 489.13% 9.64M
Special items of operating profit
123.09% 20.01M -115.81% -1.35M -217.60% -1.67M 767.66% 8.27M
Operating profit
-1.66% 231.32M -4.27% 174.64M 2.13% 84.28M 11.36% 367.59M
Special items of earning before tax
-1,295.24% -2.25M -1,126.43% -2.24M -895.46% -1.33M 14.47% -212.93K
Earning before tax
-2.55% 229.07M -5.41% 172.4M 0.68% 82.95M 11.38% 367.38M
Tax
37.32% -19.37M 42.26% -15.41M 35.79% -8.93M 3.13% -45.02M
After-tax profit from continuing operations
2.71% 209.71M 0.92% 156.98M 8.09% 74.02M 13.76% 322.36M
Earning after tax
2.71% 209.71M 0.92% 156.98M 8.09% 74.02M 13.76% 322.36M
Profit attributable to shareholders
2.71% 209.71M 0.92% 156.98M 8.09% 74.02M 13.76% 322.36M
Basic earnings per share
-6.78% 0.55 -8.89% 0.41 -5.00% 0.19 13.41% 0.93
Diluted earnings per share
Currency Unit
CNYCNYCNYCNY
Accounting Standards
CAS (2007)CAS (2007)CAS (2007)CAS (2007)
Audit Opinions
------Unqualified Opinion
Auditor
------Daxin Accounting firm (Special General Partnership)

Q6, Q9, and FY are cumulative quarterly reports: Q6 is the interim report; Q9 is third quarter report; FY is the annual report.

The MOM data from the Quarterly report,MOM=(current period - last period)/last period *100%

Company Overview More
The company is a leading orthopedic medical device company in China, focusing on the R & D, production and sales of orthopedic medical devices, including joint prosthesis products and spinal products. The Group is one of the enterprises with the most complete medical device registration certificate in the field of joint prosthesis in China, covering the four major human joint prosthesis products of shoulder, elbow, hip and knee, while the spine product is a full range of products of spinal internal fixation system. With China as its main market, the Group has established a huge distribution network in all provinces, municipalities and autonomous regions in China, and exports products to overseas markets in the mode of overseas distributors or ODM and OEM. The company is mainly engaged in the R & D, production and sales of implantable orthopedic medical devices. The company's main products include joint prosthesis products, spinal implant products, suitable for different parts of the human body, such as hip joint, knee joint, shoulder joint, elbow joint, cervical vertebra, thoracic vertebra, lumbar vertebra and so on.
CEO: Chunbao\wenling Shi
Market: Hong Kong motherboard
Listing Date: 03/11/2015
Hot List
TradeSearchNews
SymbolLatest price%Chg

Loading...

Watchlist